Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak Discussed with the Syndicate of Hospitals Owners the Health Sector Issues and Received an Invitation to Attend the Arab Hospitals Forum in Cairo

 
The Minister of Public Health Jamil Jabak received a delegation from the private hospitals owners syndicate headed by Sleiman Haroun, in the presence of MP Fadi Alama. During a meeting, hospitals matters and the ways to find solutions for the problems of the citizens and the hospitals’ owners were discussed.
 
“We consider them as an integral part of the hospitalization sector in Lebanon and a key partner in the health care and medical sector in Lebanon,” Jabak told the delegation.
 
Dr. Jabak said that the meeting tackled the problems of the syndicate and mentioned that the ministry would work to find solutions to these problems in no time.
 
Haroun

Haroun stated that the visit aimed at congratulating Dr. Jabak for taking office at the Ministry. “The meeting provided an opportunity to consider the matters that need to be dealt with on the long term,” Jabak added.
 
“The delegation noticed Minister Jabak’s concern for the hospitals as much as for the patient and the need to provide him with the necessary services. It was agreed to activate the current scientific mechanism related to the admission of the patient to the emergency room at the hospitals in order to prevent any issues that might arise while admission,” Haroun said.
 
“The syndicate’s delegation asked the Minister of Public health to find solutions for the delay in the settlement of the amounts owed to the hospitals,” Haroun added.
 
Arab Hospitals Federation

Jabak then met with a delegation from the Arab Hospitals Federation that invited him to attend the “Arab Hospitals Federation Forum in Cairo” that will be held in conjunction with the Council of Arab Ministers of Health on 27 and 28 February. The delegation also invited him to attend the Arab Hospitals Federation Conference” that will be held next 10 and 11 April in Kuwait.
    5
ATC Name B/G Ingredients Dosage Form Price
C01BC04 FLECAINIDE BIOGARAN L.P. G Flecainide acetate - 100mg 100mg Capsule, extended release 1,154,361 L.L
C01BC04 FLECAINIDE BIOGARAN L.P. G Flecainide acetate - 50mg 50mg Capsule, extended release 1,154,361 L.L
S01BC04 FLUROPTIC G Flurbiprofen sodium - 0.03% w/v 0.03% w/v Drops solution 223,078 L.L
J01AA02 FARMODOXI G Doxycycline (hyclate) - 100mg 100mg Tablet 310,428 L.L
M03BA53 FLEXPRO EXTRA G Paracetamol - 500mg, Methocarbamol - 400mg Tablet, film coated 337,304 L.L
D06AX01 FUTASOLE G Fusidic acid - 20mg/g 2% Cream 145,135 L.L
D06AX01 FUCIKALT G Fusidic acid (sodium salt) - 2% 2% Ointment 209,895 L.L
J05AB16 FLEXIVIR G Remdesivir - 50mg 50mg Injectable lyophilised powder for solution 4,837,833 L.L
M04AA03 FEBUXOSTAT ARROW G Febuxostat - 120mg 120mg Tablet, film coated 1,084,481 L.L
M04AA03 FEBUXOSTAT BIOGARAN G Febuxostat - 120mg 120mg Tablet, film coated 1,402,972 L.L
L01BB05 FLUDARABINE PHOSPHATE NEAPOLIS G Fludarabine Dihydrogenophosphate - 50mg/2ml 50mg/2ml Injectable solution L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution 295,038,213 L.L
H05AA02 FORTEO BioTech Teriparatide - 250mcg/ml 20mcg/80mcl Injectable solution 24,834,241 L.L
B02BB01 FIBRYGA BioHuman Fibrinogen, human - 1g 1g Injectable powder for solution+solvent 40,915,563 L.L
B02BD03 FEIBA BioHuman Factor VIII Inhibitor bypassing fraction - 500IU 500U (50U/ml) Injectable powder for solution+solvent 40,480,699 L.L
B02BD03 FEIBA BioHuman Factor VIII Inhibitor bypassing fraction - 1000IU 1000U (50U/ml) Injectable powder for solution+solvent 79,869,612 L.L
G03GA04 FOSTIMON BioHuman Urofollitropin - 150IU 150IU Injectable lyophilised powder for solution+diluent 36,347,120 L.L
G03GA04 FOSTIMON BioHuman Urofollitropin - 75IU 75IU Injectable lyophilised powder for solution+diluent 15,744,000 L.L
R03DX10 FASENRA B Benralizumab - 30mg 30mg Injectable solution 214,213,273 L.L
A06AD15 FORLAX POUDRE POUR SOLUTION BUVABLE B Macrogol 4000 - 10g 10g Powder for solution 450,187 L.L
G04B FONCITRIL 4000 B Citric acid - 1.189g, Potassium Citrate - 1.73g, Sodium citrate - 1.845g Granules 1,613,955 L.L
A06AD65 FORTRANS POUDRE POUR SOLUTION BUVABLE B Potassium chloride - 0.750g, Sodium chloride - 1460g, Sodium bicarbonate - 1680g, Sodium sulfate anhydrous - 5700g, Macrogol 4000 - 64.000g Powder for solution 1,136,891 L.L
M05BA04 FOSAMAX 70MG ONCE WEEKLY B Alendronate - 70mg 70mg Tablet 1,988,887 L.L
R05CB01 FLUIMUCIL B N-acetylcysteine - 600mg 600mg Tablet, effervescent 567,102 L.L
R05CB01 FLUIMUCIL MUCOLYTIC B N-acetylcysteine - 2% 2% Syrup 595,322 L.L
C03BA11 FLUDEX B Indapamide - 1.5mg 1.5mg Tablet, sustained release 517,379 L.L
D07CC01 FUCICORT B Fusidic acid - 20mg/g, Betamethasone (valerate) - 1mg/g Cream 376,276 L.L
M05BB03 FOSAVANCE B Alendronic acid (sodium alendronate) - 70mg, Colecalciferol - 5600IU Tablet 1,988,887 L.L
A10BK01 FORXIGA B Dapagliflozin - 10mg 10mg Tablet, film coated 2,927,964 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025